NCT06438913尚未招募不适用
The Improvement of Cough Outcomes After Tezepelumab Treatment in Korean Severe Asthma Patients With Airway Hyperresponsiveness
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 100
- 主要终点
- Effects of Tezepeluma on Cough
研究概览
简要总结
There is no study that systematically evaluated the effect of Tezepelumab on cough, and based on this background, the present researchers aimed to evaluate the effect of Tezepelumab treatment in patients with severe asthma who complain of cough using the Leicester Cough Questionnaire, a cough-related quality of life measurement tool.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 19 Years 至 79 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Severe asthma patients aged 19 or older and 79 or younger
- •Cases diagnosed as asthma by an expert and classified as severe asthma according to the 2014 ATS/ERS guidelines
- •Patients who require the use of high-dose inhaled steroids and additional control agents or systemic steroids for more than 50% of the year to control symptoms. Or, if asthma is not controlled even with the medication. Here, uncontrolled asthma means that any one of the following is satisfied.
- •ACT score less than 20 or 'not well controlled' according to GINA guideline
- •frequent exacerbations; Requires systemic steroid administration (over 3 consecutive days) more than twice in the previous year If you did
- •severe exacerbation; A condition that required hospitalization, admission to an intensive care unit, or application of a ventilator in the previous year If you have been angry at least once
- •airflow restrictions; FEV1 < 80%
- •If a cough is due to asthma according to a doctor and the cough onset scale (cough visual analogue scale, cough VAS) satisfies 30 or more points out of
- •If a positive result is confirmed in the methacholine (or mannitol) bronchial challenge test (if the bronchial challenge test result is not available or the test is difficult to proceed, it can be replaced with a positive bronchodilator response test)
排除标准
- •Minors under 19 years of age, senior citizens over 79 years of age
- •If there is a history of use of other biological agents within 3 months prior to study registration
- •Cases where there was an acute exacerbation requiring a steroid burst (total 90mg prednisolone or more) during the 4-week screening period before study registration (possible for long-term prednisolone users)
- •Cases accompanied by clinically serious respiratory disease in addition to severe asthma
- •When accompanied by hypereosinophilic syndrome, ABPA, EGPA
- •When it is difficult to evaluate asthma alone due to severe respiratory disease
- •Pregnant women
结局指标
主要结局
Effects of Tezepeluma on Cough
时间窗: 1years
The effectiveness of Tezepelumab on cough was assessed by comparing the LCQ score at 1 and 12 months of administration with the LCQ score at the time of registration.
次要结局
未报告次要终点
研究者
Tae-Bum Kim
Principal Investigator
Asan Medical Center
相似试验
已完成
不适用
Tezepelumab PRO StudyAsthmaNCT05922891AstraZeneca92
招募中
Unknown
Effectiveness of Tezepelumab on Asthma control and Cough: A prospective, multi-center, observational studyasthmaJPRN-jRCT1030230280Tashiro Naoki90
进行中（未招募）
1 期
REVErsing airway Remodelling with Tezepelumab (REVERT)exacerbating asthmaMedDRA version: 20.0Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2022-002891-35-FRniversity Hospital of Montpellier90
已完成
3 期
REVErsing Airway Remodelling With TezepelumabAirway Remodelling, AsthmaticNCT05651841University Hospital, Montpellier90
已完成
2 期
Study to Evaluate Tezepelumab in Adults With Chronic Spontaneous UrticariaChronic Spontaneous UrticariaNCT04833855Amgen183